103 related articles for article (PubMed ID: 16803488)
1. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial.
Fiander AN; Tristram AJ; Davidson EJ; Tomlinson AE; Man S; Baldwin PJ; Sterling JC; Kitchener HC
Int J Gynecol Cancer; 2006; 16(3):1075-81. PubMed ID: 16803488
[TBL] [Abstract][Full Text] [Related]
2. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.
Smyth LJ; Van Poelgeest MI; Davidson EJ; Kwappenberg KM; Burt D; Sehr P; Pawlita M; Man S; Hickling JK; Fiander AN; Tristram A; Kitchener HC; Offringa R; Stern PL; Van Der Burg SH
Clin Cancer Res; 2004 May; 10(9):2954-61. PubMed ID: 15131030
[TBL] [Abstract][Full Text] [Related]
3. TA-CIN, a vaccine incorporating a recombinant HPV fusion protein (HPV16 L2E6E7) for the potential treatment of HPV16-associated genital diseases.
Hibbitts S
Curr Opin Mol Ther; 2010 Oct; 12(5):598-606. PubMed ID: 20886392
[TBL] [Abstract][Full Text] [Related]
4. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.
Baldwin PJ; van der Burg SH; Boswell CM; Offringa R; Hickling JK; Dobson J; Roberts JS; Latimer JA; Moseley RP; Coleman N; Stanley MA; Sterling JC
Clin Cancer Res; 2003 Nov; 9(14):5205-13. PubMed ID: 14614000
[TBL] [Abstract][Full Text] [Related]
5. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL
Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932
[TBL] [Abstract][Full Text] [Related]
6. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
Sun YY; Peng S; Han L; Qiu J; Song L; Tsai Y; Yang B; Roden RB; Trimble CL; Hung CF; Wu TC
Clin Cancer Res; 2016 Feb; 22(3):657-69. PubMed ID: 26420854
[TBL] [Abstract][Full Text] [Related]
7. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Essahsah F; Fathers LM; Offringa R; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; van der Burg SH; Melief CJ
N Engl J Med; 2009 Nov; 361(19):1838-47. PubMed ID: 19890126
[TBL] [Abstract][Full Text] [Related]
8. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
[TBL] [Abstract][Full Text] [Related]
9. Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease.
Peng S; Qiu J; Yang A; Yang B; Jeang J; Wang JW; Chang YN; Brayton C; Roden RBS; Hung CF; Wu TC
Cell Biosci; 2016; 6():16. PubMed ID: 26918115
[TBL] [Abstract][Full Text] [Related]
10. Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7).
Davidson EJ; Faulkner RL; Sehr P; Pawlita M; Smyth LJ; Burt DJ; Tomlinson AE; Hickling J; Kitchener HC; Stern PL
Vaccine; 2004 Jul; 22(21-22):2722-9. PubMed ID: 15246603
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia.
Daayana S; Elkord E; Winters U; Pawlita M; Roden R; Stern PL; Kitchener HC
Br J Cancer; 2010 Mar; 102(7):1129-36. PubMed ID: 20234368
[TBL] [Abstract][Full Text] [Related]
12. Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses.
Çuburu N; Graham BS; Buck CB; Kines RC; Pang YY; Day PM; Lowy DR; Schiller JT
J Clin Invest; 2012 Dec; 122(12):4606-20. PubMed ID: 23143305
[TBL] [Abstract][Full Text] [Related]
13. A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals.
Palefsky JM; Berry JM; Jay N; Krogstad M; Da Costa M; Darragh TM; Lee JY
AIDS; 2006 May; 20(8):1151-5. PubMed ID: 16691066
[TBL] [Abstract][Full Text] [Related]
14. Epithelial boost enhances antigen expression by vaccinia virus for the generation of potent CD8+ T cell-mediated antitumor immunity following DNA priming vaccination.
Qiu J; Peng S; Ma Y; Yang A; Farmer E; Cheng MA; Roden RBS; Wu TC; Chang YN; Hung CF
Virology; 2018 Dec; 525():205-215. PubMed ID: 30296681
[TBL] [Abstract][Full Text] [Related]
15. A prime/boost strategy by DNA/fowlpox recombinants expressing a mutant E7 protein for the immunotherapy of HPV-associated cancers.
Radaelli A; De Giuli Morghen C; Zanotto C; Pacchioni S; Bissa M; Franconi R; Massa S; Paolini F; Muller A; Venuti A
Virus Res; 2012 Dec; 170(1-2):44-52. PubMed ID: 22951311
[TBL] [Abstract][Full Text] [Related]
16. A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers.
Bissa M; Illiano E; Pacchioni S; Paolini F; Zanotto C; De Giuli Morghen C; Massa S; Franconi R; Radaelli A; Venuti A
J Transl Med; 2015 Mar; 13():80. PubMed ID: 25763880
[TBL] [Abstract][Full Text] [Related]
17. HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial.
Bakker NAM; Rotman J; van Beurden M; Zijlmans HJM; van Ruiten M; Samuels S; Nuijen B; Beijnen J; De Visser K; Haanen J; Schumacher T; de Gruijl TD; Jordanova ES; Kenter GG; van den Berg JH; van Trommel NE
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34341131
[TBL] [Abstract][Full Text] [Related]
18. A Prime-Pull-Amplify Vaccination Strategy To Maximize Induction of Circulating and Genital-Resident Intraepithelial CD8
Çuburu N; Kim R; Guittard GC; Thompson CD; Day PM; Hamm DE; Pang YS; Graham BS; Lowy DR; Schiller JT
J Immunol; 2019 Feb; 202(4):1250-1264. PubMed ID: 30635393
[TBL] [Abstract][Full Text] [Related]
19. Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis.
Cuschieri K; Kavanagh K; Moore C; Bhatia R; Love J; Pollock KG
Br J Cancer; 2016 May; 114(11):1261-4. PubMed ID: 27115467
[TBL] [Abstract][Full Text] [Related]
20. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
Garland SM; Hernandez-Avila M; Wheeler CM; Perez G; Harper DM; Leodolter S; Tang GW; Ferris DG; Steben M; Bryan J; Taddeo FJ; Railkar R; Esser MT; Sings HL; Nelson M; Boslego J; Sattler C; Barr E; Koutsky LA;
N Engl J Med; 2007 May; 356(19):1928-43. PubMed ID: 17494926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
